Nanjing Leads Biolabs (HKG:9887) said the US Food and Drug Administration has cleared its investigational new drug application for LBL-047, a bispecific fusion protein targeting BDCA2 and TACI, according to a Monday Hong Kong bourse filing.
The company said LBL-047 holds potential for treating autoimmune diseases, including systemic lupus erythematosus, dermatomyositis, IgA nephropathy, and Sjögren's syndrome.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.